Seeking Alpha

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome Transcript

Good afternoon, and welcome to the Arrowhead Pharmaceuticals REDEMPLO FDA Approval Conference Call. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made ...
Insider Monkey

Arrowhead (ARWR) FQ1 2026 Revenue Hits $264M as REDEMPLO Approval Marks Commercial Shift

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is one of the best multibagger stocks to invest in according to billionaires. On February 5, Arrowhead Pharmaceuticals achieved a strategic turning point ...
Business Wire

Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs

- Upon closing, Arrowhead will receive $825 million immediately, including an upfront payment and an equity investment at a 35% premium, and will receive an additional $250 million paid over five ...
Seeking Alpha

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome - Slideshow

The following slide deck was published by Arrowhead Pharmaceuticals, Inc. in conjunction with this event.